IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis
The Journal of Allergy and Clinical Immunology, 06/08/2012Krueger JG et al.
The data suggest that IL–17 is a key “driver” cytokine that activates pathogenic inflammation in subjects with psoriasis. Neutralizing IL–17 with ixekizumab might be a successful therapeutic strategy in psoriasis.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.